Probiotix Health PLC Director/PDMR Shareholding

RNS Number : 0492L

Probiotix Health PLC

05 November 2024

 

                                                                                                

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

 

Director/PDMR Shareholding

 

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that Mark Collingbourne, PBX's Company Secretary, has acquired 80,000 ordinary shares in the Company. Following this acquisition, Mr. Collingbourne is interested in 91,093 ordinary shares in the Company.

 

Further information about this acquisition is set out in the table below.

 

For further information, please contact:

 

ProBiotix Health plc	https://probiotixhealth-ir.com
Steen Andersen, Chief Executive Officer	Contact via Walbrook below
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker)
Mark Anwyl	Tel: [phone]
Walbrook PR Ltd	[e-mail]
Anna Dunphy	Mob: [phone]

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mark Collingbourne
2	Reason for the notification
a)	Position/status	Company Secretary
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a)	Name	ProBiotix Health plc
b)	LEI	98450048683CF0388C30
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	ordinary shares of 0.05p each         ISIN: GB00BLNBFR86
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Price(s) and volume(s)	80,000 ordinary shares @ 5.5p per share
d)	Aggregated information - Aggregated volume - Price	n/a
e)	Date of the transaction	1 November 2024
f)	Place of the transaction	Aquis Growth Market

 

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

If you would like to keep up to date with commercial news, please follow ProBiotix Health on LinkedIn

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXBUBDBIDGDGSU